Regeneron's Trading Volume Drops 33.95% to $519 Million, Ranks 147th Despite FDA Approval and Positive Clinical Trial Results

On April 25, 2025, Regeneron's trading volume was $519 million, down 33.95% from the previous day, ranking 147th in the day's stock market. Regeneron Pharmaceuticals (REGN) rose 0.48%, marking the fourth consecutive day of gains, with a total increase of 7.33% over the past four days.

Regeneron Pharmaceuticals, Inc. (REGN) has announced that the U.S. Food and Drug Administration (FDA) has approved its new drug application for Eylea (aflibercept) for the treatment of diabetic retinopathy. This approval is a significant milestone for the company, as it expands the indications for Eylea, which is already approved for the treatment of wet age-related macular degeneration and macular edema following retinal vein occlusion.

Regeneron's Eylea has shown promising results in clinical trials for diabetic retinopathy, demonstrating a significant reduction in the risk of vision loss compared to the control group. The approval of Eylea for this new indication is expected to drive growth in Regeneron's ophthalmology franchise, which is already a key contributor to the company's revenue.

In addition to the FDA approval, Regeneron has also announced positive results from a Phase 3 clinical trial of its investigational drug, REGN3500, for the treatment of severe asthma. The trial met its primary endpoint, showing a statistically significant reduction in the rate of asthma exacerbations compared to placebo. These results are encouraging for Regeneron, as they demonstrate the potential of REGN3500 to address an unmet medical need in the treatment of severe asthma.

Regeneron's pipeline of innovative therapies continues to drive growth and innovation in the biopharmaceutical industry. The company's commitment to developing new treatments for serious diseases is reflected in its strong portfolio of approved and investigational drugs. With the recent FDA approval of Eylea for diabetic retinopathy and the positive results from the Phase 3 trial of REGN3500, Regeneron is well-positioned to continue its growth trajectory in the coming years.